seasonal influenza vaccine (mRNA-1020) / Moderna - LARVOL DELTA

Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase. (PubMed, Nat Commun) - P1/2 | "In this phase 1/2 trial (NCT05333289), healthy adults 18-75 years were randomly assigned to receive different doses of mRNA-1020 or mRNA-1030 (encoding HA and NA at different ratios), mRNA-1010 (encoding HA), or a licensed active comparator (recombinant HA). There were no vaccine-related serious adverse events nor significant associated safety concerns through 181 days. mRNA-1020 and mRNA-1030 elicited high HA-specific immune responses and induced NA-specific immune responses with no additional reactogenicity at equivalent dose levels beyond an mRNA-based, HA-only-containing vaccine."

Clinical • Journal • Fatigue • Infectious Disease • Influenza • Pain • Respiratory Diseases

Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19. (PubMed, NPJ Vaccines) - "Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune responses, while Pfizer's mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks."

Journal • Review • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=572 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=572 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=560 | Recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Infectious Disease • Respiratory Diseases